A comprehensive overview of the mechanisms underlying emerging pharmacologic approaches to interventional immunology
Preface Section A: Human Immunology 1. Systems Immunology 2. Primary Immunodeficiencies 3. Phenome-wide association study (PheWAS) 4. Gene Regulatory Network 5. TCR Repertoire Analysis Section B: Current and Emerging Pharmacological Targets 6. TH17 7. TH9 8. TFH 9. Regulatory T cells 10. Regulatory B cells Section C: New Approaches 11. Immune Tolerance Induction 12. Humanized Mouse Models 13. Patient Stratification and Biomarkers
Seng-Lai Tan is the Director of Cellular and Translational Immunology at EMD Serono Research and Development Institute. He is interested in advancing mechanistic understanding and thus proof of confidence of novel therapeutic agents for the treatment of autoimmune disease. Prior to joining EMD, Dr. Tan has led cross-functional teams in both large and small molecule drug discovery programs at Eli Lilly and Company, Amgen and Roche. Dr. Tan has over 50 publications in peer-reviewed journals in the areas spanning infectious diseases, oncology and immunology.
This item has low availability through normal channels. The supplier has a low reliability rating in Fishpond's system and may not arrive on time. Learn more.